Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Department of Medical Laboratory Sciences, Immune Responses in Different Diseases Research Group, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Drug Dev Res. 2024 Apr;85(2):e22166. doi: 10.1002/ddr.22166.
Hyperlipidemia is a common clinically encountered health condition worldwide that promotes the development and progression of cardiovascular diseases, including atherosclerosis. Berberine (BBR) is a natural product with acknowledged anti-inflammatory, antioxidant, and metabolic effects. This study evaluated the effect of BBR on lipid alterations, oxidative stress, and inflammatory response in rats with acute hyperlipidemia induced by poloxamer-407 (P-407). Rats were pretreated with BBR (25 and 50 mg/kg) for 14 days and acute hyperlipidemia was induced by a single dose of P-407 (500 mg/kg). BBR ameliorated hypercholesterolemia, hypertriglyceridemia, and plasma lipoproteins in P-407-adminsitered rats. Plasma lipoprotein lipase (LPL) activity was decreased, and hepatic 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase activity was enhanced in hyperlipidemic rats. The expression of low-density lipoprotein receptor (LDL-R) and ATP-binding cassette transporter 1 (ABCA1) was downregulated in hyperlipidemic rats. BBR enhanced LPL activity, upregulated LDL-R, and ABCA1, and suppressed HMG-CoA reductase in P-407-administered rats. Pretreatment with BBR ameliorated lipid peroxidation, nitric oxide (NO), pro-inflammatory mediators (interleukin [IL]-6, IL-1β, tumor necrosis factor [TNF]-α, interferon-γ, IL-4 and IL-18) and enhanced antioxidants. In addition, BBR suppressed lymphocyte ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) and ecto-adenosine deaminase (E-ADA) as well as NO and TNF-α release by macrophages isolated from normal and hyperlipidemic rats. In silico investigations revealed the binding affinity of BBR toward LPL, HMG-CoA reductase, LDL-R, PSK9, ABCA1, and E-NTPDase. In conclusion, BBR effectively prevented acute hyperlipidemia and its associated inflammatory responses by modulating LPL, cholesterolgenesis, cytokine release, and lymphocyte E-NTPDase and E-ADA. Therefore, BBR is an effective and safe natural compound that might be employed as an adjuvant against hyperlipidemia and its associated inflammation.
高脂血症是一种常见的临床健康状况,会促进心血管疾病的发展和进展,包括动脉粥样硬化。小檗碱(BBR)是一种具有公认的抗炎、抗氧化和代谢作用的天然产物。本研究评估了 BBR 对由泊洛沙姆 407(P-407)诱导的急性高脂血症大鼠脂质改变、氧化应激和炎症反应的影响。大鼠用 BBR(25 和 50mg/kg)预处理 14 天,并单次给予 P-407(500mg/kg)诱导急性高脂血症。BBR 改善了 P-407 给药大鼠的高胆固醇血症、高三酰甘油血症和血浆脂蛋白。血浆脂蛋白脂肪酶(LPL)活性降低,肝 3-羟-3-甲基戊二酰辅酶 A(HMG-CoA)还原酶活性增强。载脂蛋白 B100 受体(LDL-R)和三磷酸腺苷结合盒转运蛋白 1(ABCA1)的表达在高脂血症大鼠中下调。BBR 增强了 P-407 给药大鼠的 LPL 活性,上调了 LDL-R 和 ABCA1,并抑制了 HMG-CoA 还原酶。BBR 预处理改善了脂质过氧化、一氧化氮(NO)、促炎介质(白细胞介素 [IL]-6、IL-1β、肿瘤坏死因子 [TNF]-α、干扰素-γ、IL-4 和 IL-18),并增强了抗氧化剂。此外,BBR 抑制了来自正常和高脂血症大鼠的淋巴细胞外核苷酸三磷酸二磷酸水解酶(E-NTPDase)和外腺苷脱氨酶(E-ADA)以及巨噬细胞释放的 NO 和 TNF-α。计算机模拟研究表明,BBR 与 LPL、HMG-CoA 还原酶、LDL-R、PSK9、ABCA1 和 E-NTPDase 具有结合亲和力。总之,BBR 通过调节 LPL、胆固醇生成、细胞因子释放以及淋巴细胞 E-NTPDase 和 E-ADA,有效预防了急性高脂血症及其相关的炎症反应。因此,BBR 是一种有效且安全的天然化合物,可作为治疗高脂血症及其相关炎症的辅助药物。